

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-257 (canceled).

258. (currently amended) A method of treating a patient with a cancerous tumor, the method comprising co-administering to the patient: (i) a thymidilate synthase (TS) inhibitor in combination with 5,10 methylene tetrahydrofolate; and, (ii) an anti-VEGF antibody, wherein the TS inhibitor and the anti-VEGF antibody are administered in dosage amounts effective to reduce the volume of the tumor wherein the tumor is selected from the group consisting of colorectal cancer and breast cancer.

259. (previously presented) The method of claim 258, wherein the TS inhibitor is 5-fluorouracil (5-FU) or an analogue or prodrug of 5-FU.

260. (previously presented) The method of claim 259, wherein the TS inhibitor is administered intravenously, or by injection, or orally.

261. (previously presented) The method of claim 259, wherein the TS inhibitor is 5-FU and the dosage amount of the 5-FU is from about 100 milligrams to about 1 gram per m².

262. (Withdrawn) The method of claim 259, wherein the prodrug is N4-pentyloxylcarbonyl -5'-deoxy-5-fluorocytidine (capecitabine).

263. (Withdrawn) The method of claim 262, wherein the dosage amount of the capecitabine is from about 1000 mg to about 5 grams per m².

264. (previously presented) The method of claim 258, wherein the 5,10 methylene tetrahydrofolate is administered in-travenously or by injection.

265. (previously presented) The method of claim 258, wherein the dosage amount of the 5,10 methylene tetrahydrofolate is from about 50 milligrams to about 250 milligrams per m².

266. (Canceled)
administration.

267. (previously presented) The method of claim 258, wherein the anti-VEGF antibody is bevacizumab (Avastin).

Claims 268-278 (Canceled).